Compare RPC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPC | FTRE |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | 326 | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.9M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | RPC | FTRE |
|---|---|---|
| Price | $8.16 | $13.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $11.00 | ★ $14.06 |
| AVG Volume (30 Days) | 389.5K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $15.80 | $3.09 |
| P/E Ratio | $53.06 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $6.79 | $3.97 |
| 52 Week High | $9.32 | $18.67 |
| Indicator | RPC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 59.11 |
| Support Level | $6.94 | $8.85 |
| Resistance Level | $8.88 | $18.26 |
| Average True Range (ATR) | 0.31 | 0.81 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 34.76 | 45.44 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.